Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL by Feng-Ting Liu, Samir G. Agrawal, John G. Gribben, Hongtao Ye, Ming-Qing Du, Adrian C. Newland, and Li Jia Blood Volume 111(5):2797-2805 March 1, 2008 ©2008 by American Society of Hematology Bax protein instability. Feng-Ting Liu et al. Blood 2008;111:2797-2805 ©2008 by American Society of Hematology Effect of TRAIL-induced Bax regulation. Feng-Ting Liu et al. Blood 2008;111:2797-2805 ©2008 by American Society of Hematology Bortezomib-induced Bax protein accumulation in DHL-4 cells. Feng-Ting Liu et al. Blood 2008;111:2797-2805 ©2008 by American Society of Hematology Prevention of Bax degradation by tBid at the mitochondrial level. Feng-Ting Liu et al. Blood 2008;111:2797-2805 ©2008 by American Society of Hematology Bortezomib (Borte)-induced apoptosis and Bax activation in CLL cells. Feng-Ting Liu et al. Blood 2008;111:2797-2805 ©2008 by American Society of Hematology Bortezomib-induced polyubiquitination and Bax–ubiquitin conjugation. Feng-Ting Liu et al. Blood 2008;111:2797-2805 ©2008 by American Society of Hematology Proteasome inhibitor facilitates TRAIL-induced Bax activation and apoptosis. Feng-Ting Liu et al. Blood 2008;111:2797-2805 ©2008 by American Society of Hematology